<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[FlexTide]]></title><description><![CDATA[Precision Peptides for Research Excellence]]></description><link>https://www.4flextide.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Mon, 27 Jul 2026 03:48:54 GMT</lastBuildDate><atom:link href="https://www.4flextide.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Retatrutide, Fatty Liver Disease, and the Case Beyond Weight Loss ]]></title><description><![CDATA[You've probably heard the buzz. A new weight loss drug is making headlines, drawing comparisons to bariatric surgery and leaving single and duel agonist GLP-1's in the rearview mirror. But if weight loss is all  you know about Retatrutide, you're only seeing a fraction of the picture. First, Let's Talk About the Weight Loss Numbers Because They're Jaw-Dropping Retatrutide isn't just another GLP-1 drug. It's triple receptor agonist - simultaneously targeting the GLP-1, GIP, and glucagon...]]></description><link>https://www.4flextide.com/post/retatrutide-beyond-a-triple-agonist</link><guid isPermaLink="false">6a4fedd4661479e527df4a70</guid><pubDate>Thu, 09 Jul 2026 06:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/9131dc_d35f251e44fe4daba5e86ecc4a0c032a~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>flextide</dc:creator></item></channel></rss>